Tag Archives: retatrutide review

Key Takeaways The race to develop the most effective metabolic research peptide has intensified. Two compounds have pulled ahead of the pack: Retatrutide (Eli Lilly’s triple agonist) and Tirzepatide (Eli Lilly’s dual agonist, already marketed as Mounjaro/Zepbound). For Australian researchers designing metabolic protocols, understanding the precise differences between these two powerhouses isn’t optional — it’s […]